Using image’s unique and patented adjuvant, delivery technology in combination with targeted MAGE-A derived peptides, imMAGE is developing a novel immunotherapeutic targeting triple negative breast cancer.

• Presenter: Mahesh Narayana CEO
• Commercial Catalyst: Jean Merrill and Caroline Hoedemaker
• Defined Milestone: Outline in detail steps required for next significant developmental breakthrough
• Targeted Completion: 1-3 months